Purpose: Elderly patents with metastatc breast cancer are expected to derive similar benefits from chemotherapy as younger patents, but are more likely to experience therapy-related toxicity. Data from the VICTOR-1 study showed that metronomic therapy with vinorelbine and capecitabine was effectve and well tolerated in patents with metastatc breast cancer. This analysis determined the efficacy and safety of the metronomic combinaton of oral vinorelbine and capecitabine in a subgroup of VICTOR-1 study patents aged ≥70 years. Methods: Eighteen of the 32 patents enrolled in VICTOR-1 were aged ≥70 years. Objectve response and clinical benefit rates were calculated and toxicity was determined using the NCI-CTCAE criteria. Results: All patents had at least 1 comorbidity (4 had 2 comorbidites), and 77.7% were taking concomitant medicaton. Eight patents (44%) had received ≥1 chemotherapy regimens for metastatc disease and most (78%) had ≥2 metastatc sites. Grade 1-2 adverse events occurred in 45.8% of cycles, whereas the incidence of grade 3 and grade 4 events was very low (1.5% and 0.7%, respectvely). Median tme to progression was 10.5 months (range 1-40). The objectve response rate was 33% and the clinical benefit rate was 67%. Conclusions: The all-oral metronomic combinaton of vinorelbine and capecitabine had an acceptable efficacy profile and appears to be beter tolerated than standard treatment schedules in elderly metastatc breast cancer patents (age ≥70 years).

Cazzaniga, M., Torri, V., Riva, F., Porcu, L., Cicchiello, F., Capici, S., et al. (2017). Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study. TUMORI, 103(1), e4-e8 [10.5301/tj.5000543].

Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study

Cazzaniga ME
;
Bidoli P
Ultimo
2017

Abstract

Purpose: Elderly patents with metastatc breast cancer are expected to derive similar benefits from chemotherapy as younger patents, but are more likely to experience therapy-related toxicity. Data from the VICTOR-1 study showed that metronomic therapy with vinorelbine and capecitabine was effectve and well tolerated in patents with metastatc breast cancer. This analysis determined the efficacy and safety of the metronomic combinaton of oral vinorelbine and capecitabine in a subgroup of VICTOR-1 study patents aged ≥70 years. Methods: Eighteen of the 32 patents enrolled in VICTOR-1 were aged ≥70 years. Objectve response and clinical benefit rates were calculated and toxicity was determined using the NCI-CTCAE criteria. Results: All patents had at least 1 comorbidity (4 had 2 comorbidites), and 77.7% were taking concomitant medicaton. Eight patents (44%) had received ≥1 chemotherapy regimens for metastatc disease and most (78%) had ≥2 metastatc sites. Grade 1-2 adverse events occurred in 45.8% of cycles, whereas the incidence of grade 3 and grade 4 events was very low (1.5% and 0.7%, respectvely). Median tme to progression was 10.5 months (range 1-40). The objectve response rate was 33% and the clinical benefit rate was 67%. Conclusions: The all-oral metronomic combinaton of vinorelbine and capecitabine had an acceptable efficacy profile and appears to be beter tolerated than standard treatment schedules in elderly metastatc breast cancer patents (age ≥70 years).
Articolo in rivista - Articolo scientifico
Breast cancer; Capecitabine; Elderly; Metronomic chemotherapy; Vinorelbine;
metastatic breast cancer
English
2017
103
1
e4
e8
reserved
Cazzaniga, M., Torri, V., Riva, F., Porcu, L., Cicchiello, F., Capici, S., et al. (2017). Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study. TUMORI, 103(1), e4-e8 [10.5301/tj.5000543].
File in questo prodotto:
File Dimensione Formato  
TJ-D-16-00335_V1-2_AU.pdf

Solo gestori archivio

Dimensione 238.13 kB
Formato Adobe PDF
238.13 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/260683
Citazioni
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 16
Social impact